Higher volume radiation facilities associated with better survival rates

March 16, 2016

New research finds improvement in overall survival rates among men with aggressive prostate cancer who were treated with radiation at a facility that frequently performs that treatment.

In a new study led by researchers at Brigham and Women's Hospital, investigators looked at men with aggressive prostate cancer who were treated with radiation as well as the case volume of the facility at which they were treated. They found that receiving radiation at a facility that treats a high volume of prostate cancer patients with radiation was associated with improved overall survival.

These findings are published online and appear in the March 15, 2016 issue of the International Journal of Radiation Oncology, Biology, and Physics.

While it is well established that hospital volume and surgeon volume are associated with better outcomes for patients who require surgery for their cancer, relatively little is known about whether this positive association is also true for cancer patients who require radiation treatment.

"Our paper shows that experience counts," said Paul Nguyen, MD, a physician researcher in the department of Radiation Oncology at Brigham and Women's Hospital and corresponding author of the new paper. "For men with aggressive prostate cancer, survival is improved if they receive their radiation treatments at a high volume facility as opposed to a lower volume facility."

Using a large cancer database, researchers analyzed data from 19,565 high-risk prostate cancer patients who were treated with radiation at 1099 facilities. This study focused on high-risk prostate cancer because these patients are much more likely to die from their disease than men with low or intermediate risk disease. After adjusting for stage of the disease, age, race, insurance status and other patient factors, researchers found that patients who received radiation at higher-volume facilities consistently had better survival rates than those treated at lower-volume facilities. For example, patients treated at a facility in the top 20 percent by prostate radiation volume (>43 patients per year) vs. bottom 80 percent achieved a 76 percent vs. 74 percent 7-year overall survival.

"We know that a surgeon who does a high volume of a specific procedure has better outcomes, and now we see that same trend when it comes to radiation therapy," Nguyen said. "At a higher volume facility, not only will the radiation oncologist will have more experience at designing and delivering the appropriate treatment fields, but the multidisciplinary team of pathologists, radiologists, urologists, and medical oncologists will have greater expertise in making accurate diagnoses and tailoring the systemic therapy regimen to ensure the best-possible outcome for the patient."

Researchers note that the study was observational, and while they adjusted for every known patient-related, socioeconomic, and tumor-related factor available in the database, it is still possible that other factors that could not be fully controlled for are contributing to the outcomes observed. Future studies in other datasets are being planned to corroborate the strong effect seen here.

Higher Volume Radiation Facilities Associated With Better Survival Rates for Men with High Risk Prostate Cancer

New research finds improvement in overall survival rates among men with aggressive prostate cancer who were treated with radiation at a facility that frequently performs that treatment.

In a new study led by researchers at Brigham and Women's Hospital, investigators looked at men with aggressive prostate cancer who were treated with radiation as well as the case volume of the facility at which they were treated. They found that receiving radiation at a facility that treats a high volume of prostate cancer patients with radiation was associated with improved overall survival.

These findings are published online and appear in the March 15, 2016 issue of the International Journal of Radiation Oncology, Biology, and Physics.

While it is well established that hospital volume and surgeon volume are associated with better outcomes for patients who require surgery for their cancer, relatively little is known about whether this positive association is also true for cancer patients who require radiation treatment.

"Our paper shows that experience counts," said Paul Nguyen, MD, a physician researcher in the department of Radiation Oncology at Brigham and Women's Hospital and corresponding author of the new paper. "For men with aggressive prostate cancer, survival is improved if they receive their radiation treatments at a high volume facility as opposed to a lower volume facility."

Using a large cancer database, researchers analyzed data from 19,565 high-risk prostate cancer patients who were treated with radiation at 1099 facilities. This study focused on high-risk prostate cancer because these patients are much more likely to die from their disease than men with low or intermediate risk disease. After adjusting for stage of the disease, age, race, insurance status and other patient factors, researchers found that patients who received radiation at higher-volume facilities consistently had better survival rates than those treated at lower-volume facilities. For example, patients treated at a facility in the top 20 percent by prostate radiation volume (>43 patients per year) vs. bottom 80 percent achieved a 76 percent vs. 74 percent 7-year overall survival.

"We know that a surgeon who does a high volume of a specific procedure has better outcomes, and now we see that same trend when it comes to radiation therapy," Nguyen said. "At a higher volume facility, not only will the radiation oncologist will have more experience at designing and delivering the appropriate treatment fields, but the multidisciplinary team of pathologists, radiologists, urologists, and medical oncologists will have greater expertise in making accurate diagnoses and tailoring the systemic therapy regimen to ensure the best-possible outcome for the patient."

Researchers note that the study was observational, and while they adjusted for every known patient-related, socioeconomic, and tumor-related factor available in the database, it is still possible that other factors that could not be fully controlled for are contributing to the outcomes observed. Future studies in other datasets are being planned to corroborate the strong effect seen here.

This research was funded by the Prostate Cancer Foundation, Fitz's Cancer Warriors, David and Cynthia Chapin, Hugh Simons in Honor of Frank and Anne Simons, Scott Forbes and Gina Ventre Fund, Jeffrey Campbell in Honor of Joan Campbell, and a grant from an anonymous family foundation.
-end-
This research was funded by the Prostate Cancer Foundation, Fitz's Cancer Warriors, David and Cynthia Chapin, Hugh Simons in Honor of Frank and Anne Simons, Scott Forbes and Gina Ventre Fund, Jeffrey Campbell in Honor of Joan Campbell, and a grant from an anonymous family foundation.

Brigham and Women's Hospital

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.